Exploring the path to selective TRK inhibition

Exploring the path to selective TRK inhibition

Loxo Oncology breakthrough therapy larotrectinib demonstrates 76% confirmed objective response rate in TRK fusion adult and pediatric cancers as presented at the 2017 Annual Meeting of the American Society of Clinical Oncology®
June 3, 2017 |  Press release>  | Explore the latest data >

Loxo Oncology receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for larotrectinib
July 13, 2016 |  Learn more about this designation >  

Get the facts on TRK testing > Read more about larotrectinib >

Larotrectinib (LOXO-101) is an investigational cancer medicine designed to selectively target a protein known as tropomyosin receptor kinase (TRK). Research suggests that some patients develop cancer because of a gene abnormality involving this protein. Interim clinical trial results suggest that larotrectinib (LOXO-101) can have profound effects when tumor genetic profiling reveals a TRK fusion in the cancer.

References

1. Hyman DM, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TKR) inhibitor, in adult and pediatric TRK fusion cancers. In: Proceedings from the 2017 ASCO Annual Meeting; June 2–6, 2017; Chicago, Illinois. Abstract LBA2501. 2. Laetsch TW, et al. A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. In: Proceedings from the 2017 ASCO Annual Meeting; June 2–6, 2017; Chicago, Illinois. Abstract 10510.